Clinical Trial Update: Study of NG01 Cell Therapy in Secondary Progressive Multiple Sclerosis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating NG01 cell therapy for Secondary Progressive Multiple Sclerosis by NeuroGenesis Ltd is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Multiple Sclerosis

Drugs mentioned

• NG01 cell therapy (NG01 cell therapy)

Snippet

Sponsor: NeuroGenesis Ltd. | Conditions: Secondary Progressive Multiple Sclerosis (SPMS) | Phase 2 | Status: NOT_YET_RECRUITING